Citation for final published version:


Please note:
Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher’s version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer


ABSTRACT

Purpose
To establish whether maintenance lapatinib after first-line chemotherapy is beneficial in human epidermal growth factor receptor (HER) 1/HER2–positive metastatic urothelial bladder cancer (UBC).

Methods
Patients with metastatic UBC were screened centrally for HER1/HER2 overexpression. Patients who screened positive for HER1-2 and who did not have progressive disease during chemotherapy (four to eight cycles) were randomly assigned one to one to lapatinib or placebo after completion of first-line/initial chemotherapy for metastatic disease. The primary end point was progression-free survival (PFS).

Results
Between 2007 and 2013, 446 patients with UBC were screened, and 232 with HER1-2-positive disease were randomly assigned. The median PFS for lapatinib and placebo was 4.5 (95% CI, 2.8 to 5.4) and 5.1 (95% CI, 3.0 to 5.8) months, respectively (hazard ratio, 1.07; 95% CI, 0.81 to 1.43; \( P = .63 \)). The overall survival for lapatinib and placebo was 12.6 (95% CI, 9.0 to 16.2) and 12.0 (95% CI, 10.5 to 14.9) months, respectively (hazard ratio, 0.96; 95% CI, 0.70 to 1.31; \( P = .80 \)). Discontinuation due to adverse events were similar in both arms (6% lapatinib and 5% placebo). The rate of grade 3 to 4 adverse events for lapatinib and placebo was 8.6% versus 8.1% (\( P = .82 \)). Preplanned subset analysis of patients strongly positive for HER1/HER2 (3+ on immunohistochemistry; n = 111), patients positive for only HER1 (n = 102), and patients positive for only HER2 (n = 42) showed no significant benefit with lapatinib in terms of PFS and overall survival (\( P > .05 \) for each).

Conclusion
This trial did not find significant improvements in outcome by the addition of maintenance lapatinib to standard of care.


INTRODUCTION

The overall survival (OS) of patients with metastatic urothelial bladder cancer (UBC), also known as transitional cell cancer (TCC), is short. Treatment of metastatic disease focuses on platinum-based combination chemotherapy in the first-line setting.1–3 After chemotherapy is complete, patients undergo a period of observation. The majority of these patients experience a relapse and die as a result of the disease. Further, second-line chemotherapy at this point remains controversial, with no clear survival advantage.3

To date, the Food and Drug Administration has not approved targeted treatments for metastatic UBC despite a number of molecular targets, such as the human epidermal growth factor receptor (HER) family and vascular endothelial growth factor, that appear attractive preclinically.4–6 Clinical studies that tested these agents in unselected patients failed to reproduce this in vivo activity.7–9 Three possible reasons account for these results. First, the combination of chemotherapy and targeted...
therapy in the UBC population, which has multiple comorbidities, is difficult. Second, none of the randomized phase III trials to date have selected patients based on expression of molecular targets. Finally, UBC has a high frequency of mutations, therefore the targeting of only one protein may be inadequate to achieve clinical benefit.

To address these issues, the UK Bladder Cancer Clinical Studies Group embarked on a phase III randomized trial to test single lapatinib (an HER1 and HER2 tyrosine kinase inhibitor) against placebo in HER1- or HER2-positive advanced/metastatic UBC. The drug was tested in the period after completion of first-line chemotherapy for metastatic disease with the primary aim of delaying progression-free survival (PFS). The goal was to maintain the response to chemotherapy; hence, the term maintenance therapy. Placebo was used as the control to allow for double blinding.

Lapatinib was chosen as the study drug because it targets HER1 and HER2, both of which have been implicated in bladder cancer progression. Preclinical and phase II data support its use in selected patients with HER1- or HER2-positive cancer (on immunohistochemistry [IHC]). In addition, as a single agent, lapatinib appears to be well tolerated, which is important in this population where comorbidities are common.

**METHODS**

**Screening Phase**

Eligible patients were those with a component of histologically confirmed advanced/metastatic TCC of the urothelial tract. Details of the percentage of TCC histology were not collected. Archived paraffin-embedded tissue was used. There was no limit on the age of the sample. Sites sent the most recent sample for testing when multiple samples were available from the same patient. Screening occurred during or after the completion of first-line chemotherapy for metastatic disease. Pathology samples were centrally tested for HER1 and HER2. Patients with positive results were eligible to participate in the trial. Baseline characteristics, treatment, and outcome data were collected for the entire screened population to assess prognostic factors. All patients gave informed consent for this trial, which has appropriate ethical approval.

**HER1 and HER2 Testing**

Overexpression of HER1 and HER2 was performed by using IHC and fluorescent in situ hybridization (FISH). IHC was performed by using the avidin–biotinylated peroxidase complex staining method standardized for both antibodies. The primary antibody was incubated for 1 h per the optimized method for each antibody (Novocastra antibodies HER1 [NCL-EGFR] 1:20 and HER2 [NCL-CBE-356] 1:80; Leica Biosystems Newcastle Ltd, Newcastle Upon Tyne, United Kingdom). IHC scoring was performed independently and blinded by a single pathologist to allow for rapid turnaround of samples. Independent double biomarker assessment would have been preferable, but it was not logistically possible in this study. Expression was scored by staining intensity (0, negative; 1+, weakly positive; 2+, moderately positive; 3+, strongly positive). Only patients with 2+ or 3+ on IHC for HER1 and/or HER2 were considered to be have a positive finding and were eligible for the study. FISH was performed in patients with equivocal positivity (1+ on IHC with both antibodies), and all had negative results. This method has been used previously to test HER1 and HER2 status in lapatinib trials and was deemed the most appropriate at the time of trial inception.

**Key Eligibility Criteria**

Patients were required to have completed four to eight cycles of chemotherapy for advanced metastatic UBC. Random assignment needed to occur between 4 and 10 weeks after the completion of chemotherapy. Any recognized chemotherapy regimen for metastatic UBC was permitted. Prior adjuvant or neoadjuvant chemotherapy was not considered first-line chemotherapy. Patients with radiologic progression of disease during chemotherapy were excluded. Adequate renal, hematologic, and liver function were required. Patients with a left ventricular ejection fraction (LVEF) below the normal range were excluded. Patients were required to be at least 18 years of age and to have resolution of chemotherapy-related toxicity before random assignment.

**Evaluation on Study**

Before random assignment, patient history, examination, trial-related blood tests, and cross-sectional imaging occurred. Adverse events (AEs) were graded according to the Common Toxicity Criteria for Adverse Events (version 3). Disease status and LVEF were assessed every 12 weeks. Response and progression were assessed by Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1). No central review occurred. Patients were discontinued from the study at progression, withdrawal of consent, unacceptable toxicity, or death.

**Treatment Plan**

Patients were randomly assigned in a double-blind manner to lapatinib or placebo (1:1). Stratification occurred by prior response to first-line chemotherapy (stable disease versus partial response/complete response) and Eastern Cooperative Oncology Group performance status. Lapatinib was administered continuously at 1,500 mg once daily (six 250-mg tablets). In the placebo group six visually identical tablets were administered instead. Dose reductions to five (lapatinib = 1,250 mg) or four (lapatinib = 1,000 mg) tablets could occur based on AEs outlined in the protocol (Data Supplement).

**End Points and Statistical Considerations**

The primary end point was PFS from the time of random assignment to progression or death. All randomly assigned patients were included in the analysis (Fig 1). This design was intervention to treat. Screening for HER1 and HER2 status occurred before study entry (screening population). Secondary end points were OS; response rates; AEs; and outcome of subsets, which depended on biomarker status (HER1 or HER2 positive alone or HER1 and HER2 3+ IHC).

The phase III study required approximately 221 patients for 196 events on the basis of a single-sided design with alpha = .025 to detect a 60% longer median PFS (hazard ratio [HR], 0.42) in the treatment group with 90% power. The duration of this PFS was assumed to be 6 months, although there was a lack of previous data to guide this estimation.

The trial followed a phase III continuous design with interim analyses. An independent data monitoring committee assessed efficacy and toxicity. Analysis at a prespecified number of events (15, 31, 49, 98, and 147) against efficacy (futility) boundaries derived on the basis of the alpha spending function approach. The trial did not halt for these assessments, and the trial team remained blinded to the study results until the final analysis. PFS and OS were compared between study arms by using the log-rank test stratified by the baseline stratification factors, and corresponding two-sided 95% CIs were presented to align with the one-sided 2.5% upper-tailed test. Significant factors in univariable Cox proportional hazards regression analysis for OS were included in a multivariable Cox model to identify significant prognostic variables.

**Prognostic Value of HER1 and HER2 in the Screened Population**

Outcomes from the entire screening population were assessed to determine the prognostic value of HER1 or HER2 and to construct a prognostic
The baseline time point for this exploratory analysis of the screening population was the date of completion of chemotherapy. OS was defined as the time from completion of chemotherapy to death or most recent follow-up. To construct the prognostic index, significant factors on multivariable analysis were dichotomized and added together. The prognostic index further categorized patients as low risk, medium risk, or high risk based on risk factor presence.

**RESULTS**

**Screening Population**

Between 2007 and 2013, 446 patients were screened for HER1 and HER2 status (Table 1). Overall, 329 (74%) patients were male, and the median age was 71 years (interquartile range, 64 to 77 years; Table 1). The median number of chemotherapy cycles was six (interquartile range, four to six cycles), 61% received cisplatin-based chemotherapy, and 48% had visceral metastasis. Subsequently, 133 (30%) patients received second-line chemotherapy.

The median duration from the time tissue was taken for diagnosis to screening consent was 5 months (Appendix Fig A1, online only). Archived tissue was histologically T1 in 11%, T2 to T3 in 64%, T4 in 22%, and from nodal/metastatic sites in 3%. HER1 and HER2 positivity did not change with increasing T stage (data not shown). Fifteen percent of screened patients were negative for HER1 and 2, whereas 39%, 13%, and 33% were positive for HER1 only, HER2 only, and HER1 and HER2, respectively. No significant difference was found in OS in terms of HER status in the screened population ($P = .35$; Appendix Fig A2, online only), which suggests that it is not a prognostic factor. The most common reasons for ineligibility for random assignment were disease progression ($n = 52$ [24%]), patient choice ($n = 19$ [8%]), and reduced LVEF ($n = 41$ [19%]; Fig 1).

**Characteristics and Outcomes of the Randomly Assigned Population**

No significant differences in characteristics in the screened or randomly assigned population were found, except that the randomly assignment population included only patients positive for HER1/HER2 and excluded those with progression of disease (Table 1). Two hundred thirty-two patients were assigned to lapatinib ($n = 116$) or placebo ($n = 116$). The PFS for lapatinib and placebo was 4.5 (95% CI, 2.8 to 5.4) months with 99 events and 5.1 (95% CI, 3.0 to 5.8) months with 102 events, respectively (HR, 1.07; 95% CI, 0.81 to 1.43; $P = .63$). The OS for lapatinib and placebo was 12.6 (95% CI, 9.0 to 16.2) months with 80 deaths and 12.0 (95% CI, 10.5 to 14.9) months with 82 deaths, respectively.

---

*Fig 1. CONSORT diagram. Overview of screened and randomly assigned patients. Only one reason for exclusion was available on the case report forms. Some patients possibly had more than one reason for exclusion. HER, human epidermal growth factor receptor; LVEF, left ventricular ejection factor.*
CIs are wide because of the modest size of the trial. The best response rate for lapatinib and placebo were 14% versus 8% ($P = .14$).

Predefined subset analysis of patients positive for HER1/HER2 3+ on IHC ($n = 111$ [48%]), those positive for HER1 only ($n = 102$ [44%]), and those positive for HER2 only ($n = 42$ [18%]) showed no significant benefit in PFS (HRs, 0.90 [95% CI, 0.59 to 1.36] with 101 events, 0.98 [95% CI, 0.72 to 1.35] with 164 events, and 1.27 [95% CI, 0.87 to 1.85] with 116 events, respectively; $P > .05$ for each) or OS (HRs, 0.77 [95% CI, 0.48 to 1.24] with 81 deaths, 0.90 [95% CI, 0.63 to 1.28] with 130 deaths, and 1.06 [95% CI, 0.69 to 1.62] with 90 deaths, respectively; $P > .05$ for each) for lapatinib. Subgroup forest plot analysis also did not show a subgroup of patients who benefited from therapy (Appendix Fig A3, online only).

### Dose Reduction and AE Profile

Lapatinib dose was reduced in 17 (7%) patients. Discontinuation due to AEs was similar in both arms (6% lapatinib and 5% placebo). No significant difference was found in the frequency of AEs, which occurred in $> 10\%$ of patients (Table 2). The rate of grade 3 to 4 AEs for lapatinib and placebo was 8.6% versus 8.1% ($P = .82$).

### Prognosis of Patients at the Time of Completion of Chemotherapy

The median OS for the screened population ($n = 446$) from the time of completion of chemotherapy was 11.8 (95% CI, 10.0 to 12.9) months. Univariable analysis for survival was performed by using the screened population at the time of completion of chemotherapy (Table 3). Significant variables were included in the multivariable analysis, and results showed that poor performance status (HR, 1.53; 95% CI, 1.28 to 1.84; $P < .001$) and progression with chemotherapy (HR, 4.2; 95% CI, 2.63 to 6.72; $P < .001$) were associated with a poor OS. Visceral metastasis (HR, 1.32; 95% CI, 1.01 to 1.71; $P = .04$) was also significant. A prognostic index that incorporated these factors was generated. Figure 3 shows the survival of the three prognostic groups within this prognostic index. The 1-year OS for low-, medium-, and high-risk patients was 61.2% (95% CI, 52.4% to 68.9%), 49.1%...
Maintenance lapatinib was not associated with clinical benefit in patients with HER1- and HER2-positive bladder cancer tumors as measured by our biomarker assay. Further analysis of subsets of patients positive for HER1 or HER2 did not show significant benefit associated with the drug, even in those tumors that expressed the highest level of the biomarker (3+ on IHC), which reinforces the lack of benefit. To our knowledge, this study is the first randomized phase III therapy trial in metastatic UBC to enrich for biomarkers and to use a maintenance design. The phase II results with lapatinib were worthy of further investigation in biomarker-positive patients with UBC previously treated with chemotherapy, which justified the current study. However, our strategy was unsuccessful for a number of possible reasons. First, although the targeting of HER proteins in isolation in breast cancer has been successful, they may not be a target associated with clinical benefit in UBC. Recent studies that investigated trastuzumab (HER2 antibody) with chemotherapy in UBC with HER2 gene amplification also do not support this theory. Different rates of biomarker positivity are seen with different methodologies, which highlights the

DISCUSSION

Fig 2. Comparison of outcomes for the randomly assigned population by Kaplan-Meier method. (A) Progression-free survival (the primary end point). (B) Overall survival (the secondary end point).
uncertainty around biomarker selection in this setting. Second, archived paraffin-embedded tissue was used to measure biomarker expression, which may not have been representative of current biomarker status. In addition, cancer tissue consisted largely of tissue from the bladder which may not be representative of metastatic disease. Third, the method of biomarker assessment (IHC and FISH analyses), which has been used successfully in breast cancer, may not be an effective approach in UBC. A spectrum of various IHC methodologies have been used to assess HER expression across different cancers. Our biomarker selection may be partly responsible for the results. Gene expression or amplification methodologies may be preferable in UBC. Fourth, the trial had an ambitious design by testing for a large clinical benefit in an enriched population. The CIs, therefore, are wide, which means that modest, but clinically meaningful differences were not detectable. Finally, although lapatinib has activity in other HER-positive cancers, it may not have activity in UBC, and other methods of targeting the HER family may be preferable. A recent phase II study in UBC with afatinib (an ERBB family inhibitor) showed promising activity. Therefore, activity that occurs with a different drug or biomarker is conceivable.

The maintenance trial design in this setting has not been used in previous randomized phase III studies in UBC, although other smaller studies that investigated sunitinib and vinflunine have been reported. The study with sunitinib showed short PFS and OS after chemotherapy, whereas the results with vinflunine suggested possible clinical activity. A new generation of immune therapy studies currently uses this trial design (NCT02500121).

Results from the screened population show that HER1 or HER2 status is not prognostic (Appendix Fig A2). This is the most robust analysis of this issue to our knowledge, which sheds light on previously contradictory data and increases our understanding of this complex area complicated by the various methodologies used to measure HER1 and HER2. Different methods of molecular analysis are possibly responsible for these contradictory results. Further work is required to determine whether HER1 or HER2 plays a role in UBC.

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Lapatinib (n = 97), No. (%)</th>
<th>Placebo (n = 99), No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1-2</td>
<td>Grade 3-4</td>
<td>Grade 1-2</td>
</tr>
<tr>
<td>Anorexia</td>
<td>12 (12.4) 0 (0.0)</td>
<td>7 (7.1) 0 (0.0)</td>
</tr>
<tr>
<td>Constipation</td>
<td>14 (14.4) 2 (2.1)</td>
<td>17 (17.2) 1 (1.0)</td>
</tr>
<tr>
<td>Cough</td>
<td>8 (8.2) 0 (0.0)</td>
<td>9 (9.1) 1 (1.0)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>59 (60.6) 6 (6.2)</td>
<td>22 (22.2) 1 (1.0)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>34 (35.1) 4 (4.1)</td>
<td>41 (41.4) 1 (1.0)</td>
</tr>
<tr>
<td>Infection</td>
<td>28 (28.8) 5 (5.2)</td>
<td>14 (14.1) 4 (4.0)</td>
</tr>
<tr>
<td>Itch</td>
<td>12 (12.4) 0 (0.0)</td>
<td>11 (11.1) 1 (1.0)</td>
</tr>
<tr>
<td>Nausea</td>
<td>22 (22.7) 1 (1.0)</td>
<td>19 (19.2) 1 (1.0)</td>
</tr>
<tr>
<td>Neuropathy</td>
<td>7 (7.2) 0 (0.0)</td>
<td>13 (13.1) 1 (1.0)</td>
</tr>
<tr>
<td>Pain</td>
<td>37 (38.1) 10 (10.3)</td>
<td>41 (41.4) 6 (6.1)</td>
</tr>
<tr>
<td>Rash</td>
<td>43 (44.3) 2 (2.1)</td>
<td>21 (21.2) 0 (0.0)</td>
</tr>
<tr>
<td>Shortness of breath</td>
<td>12 (12.4) 0 (0.0)</td>
<td>7 (7.1) 3 (3.0)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>15 (15.5) 3 (3.1)</td>
<td>15 (15.2) 1 (1.0)</td>
</tr>
</tbody>
</table>

NOTE. The most common adverse events were graded according to the Common Terminology Criteria for Adverse Events (version 3). Data were inadequately recorded or missing for 36 patients, equally balanced in both arms.

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Lapatinib (n = 97), No. (%)</th>
<th>Placebo (n = 99), No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1-2</td>
<td>Grade 3-4</td>
<td>Grade 1-2</td>
</tr>
<tr>
<td>Anorexia</td>
<td>12 (12.4) 0 (0.0)</td>
<td>7 (7.1) 0 (0.0)</td>
</tr>
<tr>
<td>Constipation</td>
<td>14 (14.4) 2 (2.1)</td>
<td>17 (17.2) 1 (1.0)</td>
</tr>
<tr>
<td>Cough</td>
<td>8 (8.2) 0 (0.0)</td>
<td>9 (9.1) 1 (1.0)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>59 (60.6) 6 (6.2)</td>
<td>22 (22.2) 1 (1.0)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>34 (35.1) 4 (4.1)</td>
<td>41 (41.4) 1 (1.0)</td>
</tr>
<tr>
<td>Infection</td>
<td>28 (28.8) 5 (5.2)</td>
<td>14 (14.1) 4 (4.0)</td>
</tr>
<tr>
<td>Itch</td>
<td>12 (12.4) 0 (0.0)</td>
<td>11 (11.1) 1 (1.0)</td>
</tr>
<tr>
<td>Nausea</td>
<td>22 (22.7) 1 (1.0)</td>
<td>19 (19.2) 1 (1.0)</td>
</tr>
<tr>
<td>Neuropathy</td>
<td>7 (7.2) 0 (0.0)</td>
<td>13 (13.1) 1 (1.0)</td>
</tr>
<tr>
<td>Pain</td>
<td>37 (38.1) 10 (10.3)</td>
<td>41 (41.4) 6 (6.1)</td>
</tr>
<tr>
<td>Rash</td>
<td>43 (44.3) 2 (2.1)</td>
<td>21 (21.2) 0 (0.0)</td>
</tr>
<tr>
<td>Shortness of breath</td>
<td>12 (12.4) 0 (0.0)</td>
<td>7 (7.1) 3 (3.0)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>15 (15.5) 3 (3.1)</td>
<td>15 (15.2) 1 (1.0)</td>
</tr>
</tbody>
</table>

NOTE. The most common adverse events were graded according to the Common Terminology Criteria for Adverse Events (version 3). Data were inadequately recorded or missing for 36 patients, equally balanced in both arms.
explore the importance of gene expression in unselected patients, but we focused predominately on protein expression. Future research in this area would be helpful.

The trial design allowed us to study the characteristics and outcomes of unselected patients after the completion of chemotherapy, which has not been reported previously. More than one half (61%) of the patients received cisplatin, and a high proportion (48%) had visceral metastasis, which gives some insight into the current population of patients who receive chemotherapy. Survival was short after the completion of chemotherapy (<1 year) in both the randomly assigned and screened populations, which underscores the poor outcome for patients with metastatic UBC, particularly those not eligible for cisplatin chemotherapy. Only 30% of patients received second-line chemotherapy (29 in the lapatinib arm and 34 in the placebo arm; \( P = .49 \)), which may have contributed to this finding. Together, these results show that patients with UBC have a poor outcome, even if they initially gained clinical benefit from chemotherapy. Whether the patients in this study had a less-than-expected good outcome remains largely unknown because of the paucity of comparative data in this setting.

Prognostic factors were also assessed in this population. Previous studies of prognostic factors focused on clinical parameters before the start of first-line therapy. The current trial design allowed us to analyze prognostic factors at the time of completion of chemotherapy. Results showed that radiologic progression on chemotherapy, visceral metastasis, and poor performance status were associated with a poor outcome in multivariable analysis. A prognostic model that consisted of these factors was constructed and discriminated patients into three groups. Although further validation is required, this information is novel and helpful to patients and their caregivers.

The trial design was pragmatic and allowed for a varying number of chemotherapy cycles and regimens. Previous perioperative therapy was not an exclusion criterion, and the proportion of patients who received this was not recorded. In addition, patients could be randomly assigned up to 10 weeks after chemotherapy. Although this makes the study applicable to a broad spectrum of patients, it may introduce bias. Results show that the median number of chemotherapy cycles and the use of cisplatin were similar in both random assignment groups, which alleviates some of these concerns. However, differences in the quality of responses between cisplatin and carboplatin are a concern. Indeed, a significant proportion of patients who received placebo had continued response, which suggests ongoing activity of chemotherapy beyond the last dose administered.

Despite these shortcomings, this study shows that lapatinib does not significantly improve outcomes in this subset of patients with UBC. Further exploration with different agents and different biomarkers continue. A more detailed understanding of the role of HER1 and HER2 in UBC should be pursued in future trials.

**Fig 3.** Prognostic index that predicts outcome from the time of chemotherapy completion. The last day of chemotherapy was considered the start date for data analysis. Overall survival was the chosen end point. Factors associated with a poor outcome on multivariable analysis were included in the prognostic model: Low performance status, progression of disease on chemotherapy, and presence of visceral metastasis were all allocated 1 point. Three groups (low risk = no factors; medium risk = one factor; high risk = more than one factor) were formed.

<table>
<thead>
<tr>
<th>Risk Level</th>
<th>No. at risk</th>
<th>0.25</th>
<th>0.50</th>
<th>0.75</th>
<th>1.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low risk</td>
<td>139</td>
<td>43</td>
<td>8</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Medium risk</td>
<td>150</td>
<td>24</td>
<td>6</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>High risk</td>
<td>64</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

**Conception and design:** Thomas Powles, Shah-Jalal Sarker, Simon Chowdhury

**Provision of study materials or patients:** Robert A. Huddart, Simon Crabb, Simon Chowdhury

**Collection and assembly of data:** Thomas Powles, Robert A. Huddart, Tony Elliott, Charlotte Ackerman, Robert Jones, Syed Hussain, Simon Crabb, Satinder Jagdev, John Chester, Serena Hilman, Mark Beresford, Graham Macdonald, Sundar Santhanam, John A. Frew, Andrew Stockdale, Simon Hughes, Daniel Berney, Simon Chowdhury

**Data analysis and interpretation:** Thomas Powles, Robert A. Huddart, Shah-Jalal Sarker, Charlotte Ackerman, Daniel Berney, Simon Chowdhury

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

Disclosures provided by the authors are available with this article at ascopubs.org/journal/jco.
REFERENCES


Affiliations

Thomas Powles, Shah-Jalal Sarkar, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhwury, Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James’s University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hillman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.

Support

Supported by a GlaxoSmithKline research grant and the Cancer Research UK Experimental Cancer Medicine Centre.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2—Positive Metastatic Bladder Cancer

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Thomas Powles
Honorary: Roche, Genentech, Bristol-Myers Squibb, Novartis, GlaxoSmithKline
Consulting or Advisory Role: Roche, Genentech, Bristol-Myers Squibb, Merck, GlaxoSmithKline
Research Funding: AstraZeneca, MedImmune, Roche, Genentech, GlaxoSmithKline

Robert A. Huddart
Leadership: Cancer Centre London
Honorary: Roche, Merck Sharp & Dohme, Astellas Pharma, Janssen Pharmaceuticals
Research Funding: Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses: Merck Sharp & Dohme, Janssen-Cilag

Tony Elliott
Research Funding: Bayer AG (Inst), Astellas Pharma (Inst), Orion Pharma (Inst), AstraZeneca (Inst), Janssen Pharmaceuticals (Inst), Pierre Fabre (Inst), Sanofi (Inst), Celgene (Inst)
Travel, Accommodations, Expenses: Merck Sharp & Dohme, Janssen-Cilag

Shah-Jalal Sarker
No relationship to disclose

Charlotte Ackerman
No relationship to disclose

Robert Jones
Honorary: GlaxoSmithKline
Speakers’ Bureau: GlaxoSmithKline
Research Funding: GlaxoSmithKline

Syed Hussain
Consulting or Advisory Role: Pierre Fabre, Astellas Pharma, Bayer AG, Janssen-Cilag, Roche, Genentech, Merck, Ipsen
Research Funding: Boehringer Ingelheim, Janssen-Cilag, Pierre Fabre
Travel, Accommodations, Expenses: Janssen-Cilag, Bayer AG, Boehringer Ingelheim, Pierre Fabre, Astellas Pharma, Pfizer, Roche, Merck Sharp & Dohme

Simon Crabb
Honorary: Bayer AG, Astellas Pharma
Consulting or Advisory Role: Bayer AG, Sanofi, Astellas Pharma, Janssen Pharmaceuticals, Dendreon, Pfizer
Research Funding: AstraZeneca, Astex Pharmaceuticals
Travel, Accommodations, Expenses: Astellas Pharma, Sanofi, Novartis, Janssen Pharmaceuticals, Bayer AG

Satinder Jagdev
No relationship to disclose

John Chester
Honorary: Glycotope
Consulting or Advisory Role: Glycotope
Research Funding: AstraZeneca
Travel, Accommodations, Expenses: Glycotope, Tiziana Life Sciences, Merck Sharp & Dohme

Serena Hilman
Consulting or Advisory Role: Bayer AG
Speakers’ Bureau: Pfizer
Research Funding: Merck Serono (Inst), Astellas Pharma (Inst)
Travel, Accommodations, Expenses: Bayer AG

Mark Beresford
Honorary: Roche, AstraZeneca, Eisai, Novartis
Research Funding: AstraZeneca
Travel, Accommodations, Expenses: Bayer AG

Graham Macdonald
No relationship to disclose

Sundar Santhanam
No relationship to disclose

John A. Frew
No relationship to disclose

Andrew Stockdale
No relationship to disclose

Simon Hughes
Honorary: Sanofi, Janssen Pharmaceuticals, Astellas Pharma, Bayer AG
Consulting or Advisory Role: Astellas Pharma, Janssen Pharmaceuticals
Speakers’ Bureau: Astellas Pharma, Bayer AG, Sanofi, Janssen Pharmaceuticals
Travel, Accommodations, Expenses: Astellas Pharma

Daniel Berney
Honorary: Sanofi, Molinari Diagnostics
Research Funding: Myriad Genetics

Simon Chowdhury
Honorary: Novartis, Janssen Pharmaceuticals, Sanofi, Bayer AG, GlaxoSmithKline
Consulting or Advisory Role: Novartis, Astellas Pharma, Janssen Pharmaceuticals, ESSA Pharma, Sanofi, Bayer AG, Clovis Oncology
Speakers’ Bureau: Astellas Pharma, GlaxoSmithKline, Janssen Pharmaceuticals, Bayer AG, Pfizer
Research Funding: Janssen Pharmaceuticals, Sanofi
Travel, Accommodations, Expenses: GlaxoSmithKline, Astellas Pharma, Janssen Pharmaceuticals, Bayer AG, Clovis Oncology
Acknowledgment

We thank Kashfia Chowdhury for statistical input.

Appendix

Fig A1. Time from tissue collection (archived formalin-fixed paraffin-embedded tissue) to screening.

Log-rank $P = .35$

Fig A2. Kaplan-Meier overall survival curve by human epidermal growth factor receptor (HER) status from completion of chemotherapy.
Fig A3. Subgroup forest plot analysis for overall survival. CR, complete response; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; PR, partial response; SD, stable disease.